| Document |
Document Title |
|
JP4772690B2 |
Compounds of general formula (I), (II) (III) and (V) are described or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, for use in modulating microtubule polymerisation in a subject.
|
|
JP4759679B2 |
Compounds represented by general formula (I) which have a TNF- alpha production inducing effect, a herbicidal effect and an insecticidal effect and drugs and pesticides containing these compounds as the active ingredient: wherein R<1> an...
|
|
JP2011517688T |
The new carboxylic acid derivative in which the present invention has the oxo substitution aza-heterocyclic moiety structure of formula (I), It is related with those use for the medicinal manufacture of especially the for the disposal of...
|
|
JP4704521B2 |
|
|
JP4683675B2 |
Battery has an electrolyte comprising a solvent and a salt (I) comprising a hydroxonium, nitrosonium, ammonium, metal, organic or organometallic cation and a 5-membered (hetero)cyclic anion. Battery has an electrolyte comprising a solven...
|
|
JP4673300B2 |
The present invention is directed to compounds which contain a heterocyclic triazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containi...
|
|
JP4669225B2 |
Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and Z are as described in the specification.
|
|
JP2011508723A |
There is described novel organo-platinum luminophores comprising a complex of formula I: The luminophores have application as the emissive component in organic light emitting diodes.
|
|
JP4654035B2 |
Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans.
|
|
JP2011046628A |
To provide a new compound that is low-invasive and exhibits excellent anti-brain tumor effects.A benzotriazine compound represented by general formula (I) and a salt thereof are provided. In the formula, X1 and X2 are the same or differe...
|
|
JP4646494B2 |
To obtain a new nitrogen-containing heterocyclic derivative useful as a constituent component for an organic electroluminescent element (organic EL element) and the organic EL element which attains high luminance, high luminescence effic...
|
|
JP4622047B2 |
|
|
JP4611567B2 |
New ionic liquids (I) comprise a monovalent azinium or azolium cation and a tetrasubstituted borate anion. Ionic liquids of formula K<+>A<-> (I) are new. K<+> = azinium or azolium cation of formula (K1)-(K8); R1 - R5 = H, halo or 1-8C al...
|
|
JP4565286B2 |
|
|
JP4563798B2 |
Novel PDF inhibitors and novel methods for their use are provided.
|
|
JP4560483B2 |
Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infar...
|
|
JP4560411B2 |
The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limit...
|
|
JP2010217197A |
To provide a method for analyzing a labeled analyte that is appropriate especially for multiplex analysis of a compound sample mixture, and is used for correlation study related to genome analysis and protein analysis in the protein anal...
|
|
JP4555415B2 |
A catalyst is for use in a reaction using an oxygen-atom-containing reactant and includes a nitrogen-containing heterocyclic compound of the following formula (1): This catalyst can introduce an oxygen-atom-containing group into an organ...
|
|
JP4546082B2 |
Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R1, R2, A and R5 are as defined in Claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of alle...
|
|
JP2010195787A |
To provide a compound useful for PDE IV and TNF inhibitor.There is provided a compound, an N-oxide, or a pharmaceutically acceptable salt of the formula wherein R1 is optionally substituted lower alkyl; R2 is optionally substituted cyclo...
|
|
JP2010528051A |
Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compoun...
|
|
JP4521283B2 |
This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological ef...
|
|
JP2010168382A |
To provide a compound for inhibiting the enzymatic activity of histone deacetylase, namely, a compound for treating cell proliferation diseases and conditions and to provide a composition for treating such diseases.The compound for inhib...
|
|
JP4479152B2 |
The present invention provides a compound which is useful as a PGI2 receptor agonist, and a pharmaceutical composition. The present invention is directed to a pharmaceutical composition comprising a compound represented by the follow...
|
|
JP4470219B2 |
The present invention relates to the following phenylalanine derivatives or analogues thereof having an antagonistic activity to alpha 4 integrin and therapeutic agents for various diseases concerning alpha 4 integrin.
|
|
JP4465195B2 |
Compounds of formula (I): wherein: R1 represents substituted or unsubstituted heteroaryl; Y represents -(CRnaRnb)n-; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 0 to 5; R2 represents unsubstituted or su...
|
|
JP2010514837A |
This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in co...
|
|
JP4458853B2 |
A NK1 antagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough:
|
|
JP4454848B2 |
The invention concerns novel cyclohexane derivatives difunctionalised in 1.4 of general formula (1) in which A represents a group such as (IIa) in which Ar itself represents an aromatic structure such as phenyl or pyrimidinyl optionally ...
|
|
JP2010508238A |
Novel N-phenyl-1,1,1-trifluoromethanesulfonamide compounds useful for controlling endo and/or ectoparasites in the environment are provided, together with methods of making the same, and methods of using the inventive compounds to treat ...
|
|
JP2010506561A |
The invention relates to the use of PDE2A inhibitors for the manufacture of a medicament for the treatment and/or prophylaxis of coronary diseases, especially stable and unstable angina pectoris, acute myocardial infarction, prophylaxis ...
|
|
JP2010030970A |
To provide a benzenedicarboxamide derivative exhibiting an excellent effect as an insecticide.The compound is represented by formula (1) (wherein W1, W2, W3, W4, W5, W6, W7, W8 and W9 are each nitrogen or carbon which may be replaced).
|
|
JP4413424B2 |
The invention concerns novel 3-oxo-(2H)-1,2,4-triazine derivatives of general formula (I) in which R1 represents: hydrogen, when A is an optionally substituted nitrogen atom; a linear or branched 1-C4 alkyl group; a C1-C4phenyl alkyl gro...
|
|
JP2010502728A |
A novel compound having agonist activity at the S1P3 receptor which is represented by the formula (I) wherein X is selected from the group consisting of CR3, N and NO; Y is selected from the group consisting of CR3, N and NO; Z is select...
|
|
JP4365218B2 |
The present invention relates to novel to P2X7 inhibitors of formula I and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active c...
|
|
JP2009538878A |
A method for preparing 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, commonly known as lamotrigine, is disclosed. A method of preparing the intermediate, 2,3-dichlorobenzoyl chloride, by photochlorination of 2,3-dichlorobenzotrichlo...
|
|
JP4361137B2 |
Battery has an electrolyte comprising a solvent and a salt (I) comprising a hydroxonium, nitrosonium, ammonium, metal, organic or organometallic cation and a 5-membered (hetero)cyclic anion. Battery has an electrolyte comprising a solven...
|
|
JP4359016B2 |
This invention relates aryl substituted pyridines, pyrimidines, pyrazines and triazines of Formula I:or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein A1, A2, A3, R1-R4, X and Y are set in the specification. The ...
|
|
JP2009221124A |
To provide a new polymerizable compound, and a polymer, useful for producing the functional films of charge transfer materials.Provided are the polymerizable compound represented by general formula (1), and the polymer thereof. Therein, ...
|
|
JP4328527B2 |
This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds po...
|
|
JP2009528282A |
The present invention provides a compound of the general formula 1, wherein X is the connection between the CO-hydrazine and the NR 1 -oxalic acid or ester group, and uses and synthesis methods. These compounds represent amino acid deriv...
|
|
JP4301953B2 |
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compo...
|
|
JPWO2007063934A1 |
formula(In the formula, ring A is a heterocycle, ring B is a carbon ring or a heterocycle, etc., P1, P2Is CH or N, q and r are 0 to 2, and X is -NH-, -O- or -CH.2-Etc., Y is -CH2-, -CO- or -SO2-Etc., Z is -CO- or -SO2-Etc., R3Indicates a...
|
|
JP2009513698A |
Disclosed herein are antifungal triazole derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The triazole derivatives of Chemical Formula 1 or phar...
|
|
JP2009062390A |
To provide compounds acting as blocking agents of a sodium (Na+) channel.This invention relates to aryl-substituted pyridines, pyrimidines, pyrazines, and triazines of formula (I) or a pharmaceutically acceptable salt, prodrug or solvate...
|
|
JP4244251B2 |
The present invention discloses a diazo compound represented by any one of the following general formulas (I) to (III). Also, the present invention discloses a heat-sensitive recording material including a substrate and a heat-sensitive ...
|
|
JP2009510013A |
The present invention provides compounds of formula I where R1 to R4 are as defined herein which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provid...
|
|
JP4237003B2 |
To provide an optical recording medium capable of excellently recording and reproducing with laser having a wavelength of 300 to 900 nm, and a new six-membered heterocyclic compound. This optical recording medium contains the six-membere...
|
|
JP4222833B2 |
Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, f...
|
